Introduction (Chen et al., 1996) . This signaling pathway thus provides a direct link between the receptor kinase and the tranMembers of the transforming growth factor ␤ (TGF␤) scriptional machinery required to mediate the biological superfamily play a critical role in regulating cellular response to ligand. growth and differentiation in a wide range of biological
The biochemical and functional characterization of systems. These polypeptide growth factors signal Smad1-5 as downstream mediators of TGF␤ superfamthrough heteromeric complexes of type I and type II ily signaling is yielding a comprehensive view of how transmembrane Ser/Thr kinase receptors (Attisano and this signaling pathway may function. However, novel Weis-Garcia and Massague, 1996) . ActivaSmads with unknown functions have been identified in tion of the receptor complex occurs when the type II the expressed sequence tag (EST) database or in receptor kinase transphosphorylates the GS domain of screens unrelated to TGF␤ signaling. We now investithe type I kinase (Wrana et al., 1994) . This activates gate the MAD-related protein Smad7 which is induced the type I kinase, which transiently associates with and by laminar fluid shear stress and is expressed at elevated levels in the vascular endothelium (Topper et al., phosphorylates a unique family of intracellular signaling 1996, 1997) . We demonstrate that expression of Smad7 in TGF␤-responsive cells suppresses ligand-dependent signaling. Smad7 directly interferes with TGF␤-mediated activation of Smad2 by preventing its phosphorylation, interaction with Smad4, and nuclear accumulation. Smad7 functions by associating stably with the activated TGF␤ type I receptor to block access and phosphorylation of Smad2. Thus, Smad7 defines a novel class of MAD-related proteins that inhibit Ser/Thr kinase receptor signaling by acting as intracellular antagonists of the type I receptor kinase domain.
Results

Smad7 Inhibits TGF␤ Signaling
The MAD-related protein Smad7 was isolated in a screen to identify genes that are induced when endothelial cells are placed under laminar fluid shear stress (Topper et al., 1996) and is represented in the expressed sequence tag database. Smad7, which possesses MH1 and MH2 domains, lacks an SSXS motif at the C terminus (Topper et al., 1997) , suggesting that the protein is not a target for receptor phosphorylation and may fulfill an undescribed function in Ser/Thr kinase receptor signaling.
We first tested the potential role of Smad7, by investigating the effects of its expression on TGF␤ signaling. For these studies, we utilized HepG2 and Mv1Lu cells, both of which possess receptors and are TGF␤ responsive. Initially, we focused our analyses on p3TP-Lux, TGF␤ responsive, and drives expression of a luciferase HepG2 (A) or Mv1Lu (B) cells were transiently transfected with p3TP-reporter gene (Wrana et al., 1992) . Transient transfection Lux alone or with wild-type (WT) or activated (A) T␤RI in the absence of p3TP-Lux into either HepG2 or Mv1Lu cells resulted or presence of Smad7. Cells were incubated overnight in the abin low basal levels of transcription in untreated cells, sence or presence of 100 pM of TGF␤, and the relative luciferase which was strongly induced by stimulation with 100 pM activity was measured in cell lysates. Luciferase activity was normal-TGF␤ ( Figure 1 ). In cells cotransfected with Smad7, there ized to ␤-galactosidase activity and is expressed as the mean Ϯ SD of triplicates from a representative experiment.
was little effect on basal transcription; however, we observed a strong suppression of TGF␤-dependent induction of the 3TP promoter. TGF␤ signaling can be initiated DNA-binding protein, FAST1, and activation of tranby expression of a constitutively active version of the scription from an activin-responsive element (ARE; Chen TGF␤ type I receptor, T␤RI, which contains a substituet al., 1996) . Since Smad2 functions in both TGF␤-and tion of threonine residue 204 to aspartate and signals activin-signaling pathways ; TGF␤ responses in the absence of ligand and the type II Eppert et al., 1996; Graff et al., 1996 ; Macías-Silva et receptor (Wieser et al., 1995) . In both HepG2 and Mv1Lu al., 1996) , we utilized this system to investigate the role cells, transfection of activated T␤RI led to strong stimuof Smad7 in blocking immediate early responses to lation of the 3TP promoter that was potently inhibited by TGF␤. To establish that this assay functions in HepG2 coexpression of Smad7 (Figure 1 ). Since our subsequent cells, we constructed pAR3-lux, which contains a lucifbiochemical analyses involved versions of Smad7 that erase reporter gene under the control of three AREs were epitope tagged at the amino and carboxyl termini linked to a basic TATA box-containing promoter. This with myc and HA epitopes, respectively, we also tested construct had minimal basal activity in HepG2 cells, but the activity of the modified proteins. These versions of when it was cotransfected with FAST1, we observed a Smad7 were indistinguishable from untagged proteins strong TGF␤-dependent induction of the reporter gene in blocking TGF␤-dependent signaling in all of the ( Figure 2A ). These data indicate that HepG2 cells contain assays that we employed (data not shown). Together, the necessary components to activate transcription these data suggest that Smad7 can function to block from an ARE, but are missing the DNA-binding compo-TGF␤ signaling downstream of its receptors. nent, FAST1. To determine whether Smad7 can block To determine whether Smad7 inhibitory activity was activation of pAR3, HepG2 cells were cotransfected with a direct effect on TGF␤-signaling pathways, we develpAR3-Lux, FAST1, and Smad7. In contrast to the stimuoped an immediate early response assay for TGF␤ siglation observed in cells receiving only FAST1, TGF␤-naling. In Xenopus, activin signaling leads to the specific dependent activation was suppressed in cells cotransfected with Smad7 ( Figure 2A ). association of Smad2 with the forkhead-containing either in the presence or absence of Smad7. In untreated cells, basal transcription from the reporter gene was low and was unaffected by cotransfection with Smad7. However, treatment of cells with 100 pM TGF␤ resulted in a strong induction of the promoter in cells transfected with GAL4/Smad2 alone. In contrast, cotransfection with Smad7 resulted in almost complete abrogation of TGF␤-dependent activation of the promoter that was partially reversed when higher doses of GAL4/Smad2 were transfected into the cells. Together, these data suggest that Smad7 may block TGF␤ responses by interfering directly with the signaling pathways.
Smad7 Blocks Activation of Smad2
TGF␤ signaling through Smad2 is initiated when the type I receptor kinase, activated by receptor II-mediated transphosphorylation, directly phosphorylates Smad2 on the C-terminal serine residues . This phosphorylation results in dissociation of Smad2 from the receptor and is required for subsequent interactions with Smad4 and nuclear translocation of the protein Kretzchmar et al., 1997) . To investigate whether Smad7 interferes with any of these signaling events, we determined if it could block either Smad2 association with Smad4 or its nuclear accumulation. To investigate heteromeric complex formation, HepG2 cells were transiently transfected with Smad2 and Smad4 either in the presence or absence of Smad7. In cells expressing Smad2 and Smad4, no association between these two proteins could be de- , 1996) . In contrast, in cells coexpressing Smad7, we luciferase activity was measured in cell lysates. Luciferase activity observed almost a complete block in TGF␤-dependent was normalized to ␤-galactosidase activity and was expressed as association of Smad2 and Smad4.
the mean Ϯ SD of triplicates from a representative experiment.
We also investigated whether Smad7 could disrupt Smad2 was localized throughout the cell in unstimulated cultures, and activation of TGF␤ signaling resulted in nuclear accumulation of the protein. However, in the Since Smad2 is centrally involved in mediating TGF␤ signaling, we investigated whether Smad7 might specifipresence of Smad7, the nuclear accumulation of Smad2 in response to TGF␤ signals was blocked ( Figure 3B ). cally disrupt ligand-dependent activation of Smad2 transcriptional activity. To test this, we employed a heteroloFor these studies, we simultaneously analyzed the expression of Smad7/HA using a rabbit anti-HA antibody gous transcriptional activation assay (Liu et al., 1996) , in which Smad2 is fused to the DNA-binding domain of and confirmed that Smad2 and Smad7 were coexpressed in the same cells (data not shown). Together, the yeast transcription factor GAL4. Expression of this fusion protein in HepG2 cells mediated TGF␤-depenthese data suggest that Smad7 inhibits TGF␤ signaling by preventing Smad2 association with Smad4 and nudent induction of the heterologous promoter construct, pG5-E1b-lux, which contains five GAL4 elements linked clear accumulation of the complex.
To explore the mechanism of Smad7 function, we to an E1b TATA box and a luciferase reporter gene. To determine if Smad7 disrupts this response, pG5-E1b-first tested if it could engage Smad2 in nonproductive heteromeric complexes. However, we were unable to lux was transfected into HepG2 cells together with increasing amounts of GAL4/Smad2 expression vector detect any physical association of Smad7 with Smad2 or Smad4 in either yeast or mammalian cells (data not shown). Since phosphorylation of Smad2 by the TGF␤ type I receptor is required for its activation and downstream functions, we investigated whether Smad7 interferes with phosphorylation of the protein. To test this, Smad2 was expressed in COS cells along with wild type or constitutively activated T␤RI, and phosphorylation of the protein was analyzed by metabolic labeling with [ 32 P]phosphate. As described previously, coexpression of Smad2 with activated T␤RI resulted in a strong increase in phosphate incorporation into the protein that is due to receptor-mediated phosphorylation at the probing the same membrane with a rabbit anti-Smad2 polyclonal prevents T␤RI-dependent phosphorylation of Smad2 in antisera (␣-Smad2). To confirm equivalent levels of Smad4 expresintact cells but is not itself a target for TGF␤-regulated sion, aliquots of total lysates were immunoprecipitated using an phosphorylation. anti-HA antibody and then immunoblotted with anti-HA antibody (␣-HA). Expression of Smad7 was measured in a similar manner using an anti-myc monoclonal antibody (␣-myc). to our previous studies on Smad2 (Macías-Silva et al., Coexpression with Smad7 blocks this nuclear accumulation, re-1996). Briefly, COS cells were transfected with wild-type sulting in a diffuse staining pattern that is similar to controls.
Smad7 Interacts Stably with the TGF␤ Receptor
or kinase-deficient versions of T␤RII or T␤RI, together with Smad7 tagged at the carboxyl terminus with the HA epitope. Receptors were affinity-labeled using [ 125 I]TGF␤, and receptors coprecipitating with Smad7/ to the endogenous receptors that are expressed in these cells ( Figure 5A ; lower panel).
To confirm that Smad7 associates directly with the type I receptor, we investigated interactions between Smad7 and either wild-type or constitutively active T␤RI. COS-1 cells were transfected with myc-tagged Smad7 together with wild-type or activated T␤RI/HA. Cell lysates were then subjected to immunoprecipitation with an anti-myc monoclonal antibody and the immunoprecipitates analyzed by immunoblotting using a rabbit anti-HA polyclonal antibody. In cells cotransfected with wild-type T␤RI, a low level of interaction between Smad7 and the receptor could be detected ( Figure 5B ). However, in cells expressing activated T␤RI, we observed a strong increase in the amount of type I receptor that coprecipitated with Smad7. Together, these data demonstrate that Smad7 associates stably with the TGF␤ receptor complex via the activated type I kinase domain.
Since Smad7 binds to the receptor and blocks phosphorylation of Smad2, we examined whether Smad7 Smad2. This decrease was specific for Smad7, since (B) Smad7 interacts preferentially with constitutively active T␤RI. COS-1 cells were transfected with combinations of myc-tagged Smad4, which does not interact with the TGF␤ receptor, Smad7 and either wild-type (WT) or activated (A) HA-tagged T␤RI had no effect in this assay (data not shown). These as indicated. Cell lysates were subjected to anti-myc immunoprecipresults suggest that Smad7 inhibits TGF␤ signaling by itation using a monoclonal antibody followed by immunoblottng preventing Smad2 access to the receptor. ing a stop codon after amino acid residue 408 ( Figure  6A ). To investigate the activity of this mutant, we transfected HepG2 cells with p3TP-Lux and increasing HA were analyzed in anti-HA immunoprecipitates. In cells cotransfected with wild-type T␤RII and T␤RI, reamounts of wild-type Smad7 or Smad7(⌬408). Similar to our previous observations, Smad7 inhibited TGF␤-ceptor complexes could clearly be detected coprecipitating with Smad7, and this interaction was comparable dependent induction of the 3TP promoter in a dosedependent fashion ( Figure 6B ). However, Smad7(⌬408), to levels obtained from cells expressing kinase-deficient T␤RI ( Figure 5A ). Furthermore, we detected minimal inwhich was expressed efficiently (data not shown and Figure 6C ), had little or no ability to block TGF␤ signaling teraction between Smad7 and receptor complexes assembled in the presence of kinase-deficient T␤RII(KR).
even at the highest doses of transfected DNA. Figure 6C ). However, in cells expressing Smad7(⌬408), there was a 10-fold reduction, to near background levels, in the amount of receptors that coprecipitated with the protein. We also determined directly whether Smad7(⌬408) could interfere with Smad2 association with the TGF␤ receptor. In contrast to wild-type Smad7, the mutant, Smad7(⌬408), was unable to block association of Smad2 with the TGF␤ receptor ( Figure 6C ). Together, these data indicate that the stable interaction of Smad7 with the receptor is critical for its inhibitory activity in TGF␤ signaling and strongly suggest that Smad7 is an intracellular antagonist of the TGF␤ type I receptor kinase domain.
Discussion
TGF␤ superfamily signaling is initiated when ligand induces formation of a heteromeric complex of type II and type I Ser/Thr kinase receptors (Attisano and Weis-Garcia and Massague, 1996) . Within this complex, the type II receptor transphosphorylates receptor I in the GS domain, thus activating the type I kinase domain that targets downstream substrates. Numerous biochemical and genetic studies on the TGF␤ superfamily have revealed that the MAD-related family of signaling molecules are critical downstream mediators of these receptor complexes (Hoodless and Wrana, 1997) . The direct phosphorylation of these proteins by Ser/Thr kinase type I receptors followed by heteromeric complex formation and nuclear accumulation has emerged as a central theme in this signaling pathway. Thus, Smad1 and 5 are specifically regulated by BMP signaling, while Smad2 and 3 function in TGF␤/activin common function in both signaling pathways. In this Smad4 (D514; Hahn et al., 1996) Figure 5A , and lysates were subjected to anti-HA or anti-Flag immunoprecipitation. Receptor Smad7 associates stably with the activated TGF␤ type I receptor. Previous studies on Smad2 showed that disSmad7 prevents the phosphorylation of Smad2, its association with Smad4, and the nuclear accumulation of sociation from the receptor required phosphorylation of the protein. Thus, Smad7 is likely to be a general inhibitor the protein on the C-terminal serine residues (Macías-of phosphorylated Smad2 function, as opposed to mod- . Analysis of the sequence of Smad7 ulating subsets of Smad2-mediated responses. These reveals that while the protein possesses both an MH1 conclusions are consistent with the general block that and MH2 domain, it does not contain the C-terminal we observed in all of the transcriptional assays we em-SSXS motif, which is the target for receptor-mediated ployed to study activation of Smad2 in response to TGF␤ phosphorylation of other Smads (Macías-Silva et al.,
Smad7 Is an Antagonist of the T␤RI Kinase Domain
signaling. Interestingly, Smad3, which also functions in 1996; Kretzchmar et al., 1997) . Consistent with this, we TGF␤ signaling, is over 90% identical to Smad2 in the were unable to detect any phosphorylation of Smad7 in MH2 domain and interacts with the TGF␤ receptor. Alresponse to TGF␤ signaling, suggesting that this recepthough this has not yet been directly investigated, it tor-associated Smad is not a substrate of the receptor.
is likely that Smad7 may function similarly to prevent In this regard, Smad7 functions similarly to the phosassociation and activation of Smad3 by the TGF␤ rephorylation site mutant of Smad2 characterized preceptor. viously. This mutant, Smad2(3SA), which is not phosOur studies indicate one potential function for Smad7 phorylated, interacts stably with the receptor and blocks as an inhibitor of TGF␤ signaling. However, they do not TGF␤ signaling to endogenous MADR2 protein (Macías-rule out the possibility that this protein may have other . Thus, Smad7 represents a naturally functions independent of its inhibitory role. The lack of occurring receptor kinase antagonist that functions to an SSXS motif suggests this protein is unlikely to funcinhibit TGF␤ signaling by preventing access of Smad2 tion as a direct substrate of Ser/Thr kinase receptors. to the receptor kinase domain.
Smad7 was initially cloned based on its induction in response to fluid shear stress in endothelial cells (Topper et al., 1996 (Topper et al., , 1997 . It will be interesting to determine Determinants within the MH2 Domain Are whether, in addition to suppressing TGF␤ signaling, it Required for Interaction of Smad7 may fulfill other functions in the normal physiology of with the TGF␤ Receptor the vasculature. Receptor-regulated Smad proteins interact transiently with the type I receptors. This may reflect an association Negative Regulation of TGF␤ Signaling that is restricted to the phosphotransferase reaction Members of the TGF␤ superfamily are potent regulators between the receptor kinase and its C-terminal peptide of the growth and differentiation of a wide range of substrate (Kretzchmar et al., 1997) . However our obsercell types during development. Thus, the spatial and vation that Smad7, which lacks the C-terminal region, temporal control of their activity is critical to normal associates stably with the receptor suggests an alternadevelopment and homeostasis. A wide range of mechative model in which the MH2 domain is the primary nisms exist to control the activity of these proteins, indeterminant that mediates interaction of Smads with the cluding a range of extracellular antagonists that bind receptor. In agreement with this, truncation of the MH2 the ligands and prevent activation of the signaling recepdomain of Smad7 disrupts binding to the receptor.
tors. Our studies now define a novel intracellular mechaThe potential role of the MH2 domain in mediating nism that can function to suppress TGF␤ signaling. Cell receptor interactions suggests that determinants within type-specific regulation of intracellular receptor antagothis domain may also be critical for establishing specificnists could allow autonomous control of the response ity. Biochemical and functional studies indicate that of cells to extracellular ligands in complex tissues. This Smad1 and 5 function in BMP signaling and that Smad2 could provide for a precision in the control of TGF␤ and 3 signal TGF␤/activin responses. Thus, the molecusignaling not afforded by secreted molecules. In particular basis for this high degree of specificity may reside lar, TGF␤ could differentially regulate cellular responses in the MH2 domain as opposed to the C-terminal tail.
in human vasculature, where Smad7 is expressed selecOf note, numerous mutations in the MH2 domain of tively in the endothelial layer (Topper et al., 1997) . receptor-regulated Smads have been identified in huIn numerous tumors, resistance to TGF␤ is associated man cancers and in the sma and Mad genes from C.
with inactivating mutations that can occur either in the elegans and Drosophila, respectively (Eppert et al., receptors or in components of the signaling pathways, such as Smad2 or Smad4 (Eppert et al., 1996; Hahn et 1996; Sekelsky et al., 1995; Savage et al., 1996 ). Many al., 1996 Markowitz and Roberts, 1996) . Here we have of these mutations have been shown to block receptoridentified a Smad protein that functions as an antagonist mediated phosphorylation of the protein (Eppert et al., of TGF␤ signaling. This suggests that amplified expres-1996; Hoodless et al., 1996) , and it will be interesting to sion of these proteins, as opposed to inactivation, might determine whether these MH2 domain mutants function act to suppress TGF␤ signals in tumors. Thus, it will by disrupting interaction of these proteins with the type clearly be important in the future to investigate whether I receptor kinase.
elevation of Smad7 expression may contribute to the progression of human cancer.
Smad7 Functions at an Early Step to Inhibit Experimental Procedures
TGF␤ Signaling
Our studies have defined Smad7 as an inhibitor that
Construction of Expression Vectors
functions at a very early step in the TGF␤ signaling Human Smad7 was cloned from human umbilical vein endothelial cells (HUVECs) isolated from multiple segments of normal-term pathway. As a direct antagonist of the receptor kinase, umbilical cords by differential display analysis as described preimmunoprecipitation as described above. Receptor complexes in the immunoprecipitates and in total cell lysates were visualized by viously (Topper et al., 1996) and is represented in the expressed sequence tag database (clone numbers: EST54659, EST53587, and separation on SDS-PAGE gels and autoradiography. EST24567). Myc/Smad7 was generated by introducing a Myc epitope tag at the amino terminus of Smad7 by standard PCR-based Transcriptional Response Assay protocols and was subcloned into pN8e-Myc/Smad7. Myc/Smad7
For TGF␤-inducible luciferase reporter assays, HepG2 cells were was then subcloned into pCMV5 using HindIII/XhoI sites to create transiently transfected with the reporter plasmid (p3TP-Lux), pCMV5-Myc/Smad7. pCMV5-Smad7 was generated by subcloning pCMV␤-gal and the indicated constructs or with empty vector alone. the open reading frame of Smad7 into pCMV5 and was epitope To induce the luciferase reporter, cells were treated overnight in tagged at the carboxyl terminus with the HA epitope, using standard 100 pM TGF␤. Luciferase activity in cell lysates was measured using approaches. The truncation mutant, pCMV5-Smad7(⌬408)/HA, was the luciferase assay system (Promega) in a Berthold Lumat LB 9501 constructed from pCMV5-Smad7 by introducing an HA epitope tag luminometer. and stop codon after amino acid residue 408. The construction of For TGF␤-inducible immediate early response gene transcription pCMV5B-Flag/Smad2 has been described previously (Eppert et al., assays, HepG2 cells were transiently transfected with the reporter 1996). Mouse Smad4, cloned as described previously (Macías-Silva plasmid (pAR3-lux), pCMV␤-gal, and the indicated constructs or et al., 1996), was tagged with the HA epitope at the carboxyl terminus with empty vector alone. Cells were treated overnight with or without by PCR. The pAR3-lux construct, containing the luciferase reporter 100 pM TGF␤, and luciferase activity in cell lysates was measured. gene, was generated by subcloning a HindIII/XhoI insert of pSP72-For GAL4/Smad2 transcriptional assays, HepG2 cells were tran-A3-CAT, (a kind gift from M. Whitman; Chen et al., 1996) into EcoRI/ siently transfected with the reporter plasmid (pG5-E1b-lux), pCMV␤-XhoI of pGL2-basic. The pG5-E1b-lux construct, containing the lugal, and the GAL4/Smad2 constructs or with empty vector alone. ciferase reporter gene downstream of the DNA-binding elements of Cells were treated overnight with or without 100 pM TGF␤, and GAL4 and the E1b TATA box, was generated by subcloning an XhoI/ luciferase activity in cell lysates was measured. To determine transEcoRI insert of pG5-E1b-CAT (a kind gift from A. Bonni) into XhoI/ fection efficiency in each assay, ␤-galactosidase activity assay was HindIII of pGL2-Basic. pCMV5B-GAL4/Smad2, consisting of Smad2 performed as described (Sambrook et al., 1989) , and luciferase fused to the DNA-binding domain of GAL4 (amino acids 1-147), was assay results were normalized for ␤-galactosidase activity. constructed by subcloning the GAL4/Smad2 insert from pGBT9-Smad2 into pCMV5B using HindIII/XbaI sites. pCMV5B-GAL4 was Immunofluorescence generated from pCMV5B-GAL4/Smad2 vector by digestion with HepG2 cells plated in Permanox chamber slides (Nunc) were tranEcoRI/XbaI. All constructs were confirmed by sequencing.
siently transfected with various combinations of Smad7/HA, Flag/ Smad2 and wild-type or activated T␤RI. Cells were fixed in 4% paraformaldehyde and permeabilized as described previously Cell Lines and Transfections . Cells were blocked in 10% goat serum and Mv1Lu and HepG2 cells were maintained in minimal essential media incubated overnight at 4ЊC with anti-HA polyclonal antibody, Y11 (1 containing 10% fetal calf serum and nonessential amino acids, and g/ml; Santa Cruz Biotechnology) and anti-Flag monoclonal anti-COS-1 cells were grown in high glucose-Dulbecco's modified Eabody, M2 (10 g/ml). Cells were washed in PBS and incubated with gle's media supplemented with 10% fetal calf serum. For transient Texas Red (TR)-conjugated goat anti-rabbit IgG and fluorescein transfections, HepG2 cells were seeded at 25% confluency in 24-isothiocynate (FITC)-conjugated goat anti-mouse IgG (1:200 diluwell plates and transfected overnight with 0.5 g of DNA per well tion; Jackson Immunologicals) as secondary antibodies (Hoodless using the calcium phosphate-DNA precipitation method as deet al., 1996) . Images were obtained using a Leica confocal microscribed previously . For transfections in COS-1 scope. and Mv1Lu, cells were seeded at 50%-70% confluency and were transfected with DEAE-dextran as described previously . Expression of Smad2, Smad4, Smad7, and T␤RI proteins Acknowledgments were determined by immunoblotting total cell lysates or immunoprecipitates using appropriate antibodies.
Address all correspondence to J. L. W. or D. F. The authors would like to thank M. Whitman for the ARE promoter, L. Attisano for pAR3-Lux and critical review of the manuscript, and P. Hoodless Phosphate Labeling, Immunoprecipitations, and Immunoblotting for assistance with immunofluorescence and confocal microscopy. A portion of Millenniwith media containing 1 mCi/ml [ 32 P]phosphate for 2 hr at 37ЊC, um's work was supported by a collaboration with Eli Lilly. J. N. T. followed by lysis and immunoprecipitation as described previously is a recipient of a Howard Hughes research fellowship for physicians, (Wrana et al., 1994) . and J. L. W. is a MRC Scholar. For anti-Flag or anti-Myc immunoprecipitations, cell lysates were subjected to immunoprecipitation with anti-Flag M2 antibody (IBI, Received; revised. Eastman Kodak) or anti-Myc 9E10 antibody, respectively, followed by adsorption to protein G-Sepharose (Pharmacia) as described previously . For anti-HA immunoprecipi
